Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

AZD 6244 9trametinib 3mirdametinib 3Lovastatin 3Sirolimus 2Inhalation 2Everolimus 2Acetylcysteine 2tipifarnib 1thymoglobulin 1pirfenidone 1peginterferon alfa-2b 1omipalisib 1fludarabine 1cediranib 1binimetinib 1Vitamin D 1Vincristine 1Vinblastine 1Temozolomide 1Sunitinib 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1Photochemotherapy 1Methotrexate 1Melphalan 1Levetiracetam 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibromatosis 1 × Temozolomide × Clear all
NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Corewell Health West

Phase 2 Completed
9 enrolled 9 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡